Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Ritonavir

An HIV protease inhibitor approved in the US in 1996; by slowing a cytochrome P450 liver enzyme it is also used as a booster for other drugs, for example with nirmatrelvir against COVID-19. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.

Did you know?In 1998, two years after approval, a new and far less soluble crystal form suddenly appeared, form II: it has been the textbook case of drug polymorphism ever since.

RitonavirGo to the active ingredient →
RitonavirActive ingredientRitonavirCat. No. P-R071-001CAS 155213-67-5
Ritonavir-d6Isotopically labelledRitonavir-d6Cat. No. P-R071-018CAS 1616968-73-0
Ritonavir-D8Isotopically labelledRitonavir-D8Cat. No. P-R071-019CAS 2983160-36-5
PhenolImpurityPhenolCat. No. P-R071-027CAS 108-95-2

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Reference substanceRitonavir CRSEDQM code Y0000714Family Ritonavir

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.